Merck & Co Buys Idenix to Boost Hepatitis C Portfolio

10.06.2014 - Merck & Co has announced it will buy Idenix Pharmaceuticals for $3.85 billion. The US drugmaker plans to combine the most promising drugs in the two portfolios to produce a faster...